Last reviewed · How we verify
placebo + life style counselling
Placebo combined with lifestyle counseling works through behavioral modification and expectancy effects to improve health outcomes.
Placebo combined with lifestyle counseling works through behavioral modification and expectancy effects to improve health outcomes. Used for Lifestyle-related chronic disease prevention and management (e.g., metabolic syndrome, hypertension, obesity).
At a glance
| Generic name | placebo + life style counselling |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Therapeutic area | Behavioral Medicine / Preventive Health |
| Phase | FDA-approved |
Mechanism of action
This intervention combines an inert placebo with structured lifestyle counseling (diet, exercise, stress management, etc.). The mechanism operates through both the placebo effect (expectancy and conditioning) and the direct physiological benefits of lifestyle changes. The counseling component addresses modifiable risk factors while the placebo may enhance adherence and perceived benefit through psychological pathways.
Approved indications
- Lifestyle-related chronic disease prevention and management (e.g., metabolic syndrome, hypertension, obesity)
Common side effects
- Minimal adverse events expected
Key clinical trials
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight (PHASE2)
- The ENCHANTMENT HIV Study (PHASE2)
- Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device. (EARLY_PHASE1)
- Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (PHASE2)
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: